scholarly journals Population-Based Registry Analysis of Antidiabetics Dispensations: Trend Use in Spain between 2015 and 2018 with Reference to Driving

2020 ◽  
Vol 13 (8) ◽  
pp. 165
Author(s):  
Eduardo Gutiérrez-Abejón ◽  
Paloma Criado-Espegel ◽  
Francisco Herrera-Gómez ◽  
F. Javier Álvarez
Keyword(s):  
Population Based ◽  
Driving Under The Influence ◽  
Oral Antidiabetics ◽  
Castilla Y Leon ◽  
Health Authorities ◽  
Minor Influence ◽  
Drivers License ◽  
And Gender ◽  
Population Based Registry ◽  
Registry Analysis

Insulins and some oral antidiabetics are considered to be driving-impairing medicines (DIM) and they belong to the Driving under the Influence of Drugs, alcohol, and medicines (DRUID) category I (minor influence on fitness to drive). The trend of antidiabetics use in Castilla y León from 2015 to 2018 is presented through a population-based registry study. Treatment duration with these medicines and the concomitant use of other DIMs were observed. An adjustment method was used with information from the drivers’ license census. For all calculations, age and gender were taken into account. 3.98% of the general population used at least one antidiabetic, as well as 2.92% of drivers. The consumption of antidiabetics in men was higher than in women (4.35% vs. 3.61%, p = 0.001), and the use increases with age, especially from 35–39 years to 75–79 years in men and 85–89 years in women. Antidiabetics were consumed chronically, specifically 100% in the case of insulins and 95% in the case of oral antidiabetics. In addition to antidiabetics, 2.5 ± 1.86 DIMs were consumed, mainly anxiolytics (25.53%), opioids (23.03%), other analgesics and antipiretics (19.13%), and antidepressants (17.73%). Collaboration between pharmacists and physicians is a priority to clearly transmitting risks to patients. It is necessary that the health authorities include information on DIMs, such as the DRUID classification, in the prescription and dispensing software.

scholarly journals Trends in Antidepressants Use in Spain between 2015 and 2018: Analyses from a Population-Based Registry Study with Reference to Driving

2020 ◽  
Vol 13 (4) ◽  
pp. 61 ◽  
Author(s):  
Eduardo Gutiérrez-Abejón ◽  
Francisco Herrera-Gómez ◽  
Paloma Criado-Espegel ◽  
F. Javier Álvarez
Keyword(s):  
Traffic Accidents ◽  
Population Distribution ◽  
Population Based ◽  
Driving Under The Influence ◽  
Registry Study ◽  
Starting Point ◽  
And Gender ◽  
Population Based Registry ◽  
Classification Category ◽  
Chronic Use

Antidepressants are considered driving-impairing medicines (DIM). This is a population-based registry study that shows the trend in the use of antidepressants in Castile and León, Spain, from 2015 to 2018. Data on antidepressant dispensations at pharmacies and the adjusted use of these medicines by the driver population are presented. For the purposes of analysis, population distribution by age and gender has been taken into account, as well as the three Driving Under the Influence of Drugs, alcohol, and medicines (DRUID) categories. Antidepressants were used by 8.56% of the general population and 5.66% of drivers. Antidepressants were used more commonly by females than by males (12.12% vs. 4.87%, χ² = 1325.124, p = 0.001), and users increased as the age increased, even if women who drive used less antidepressants after turning 60 years of age. Chronic use of antidepressants was relevant (8.28%) in the same way as daily use (3.15%). Most of the consumption included SSRIs (4.99%), which are also known as “other antidepressants” (3.71%). Regardless of antidepressants consumed, users took 2.75 ± 1.19 DIMs, which are mainly anxiolytics (58.80%) and opioids (26.43%). Lastly, regarding consumption of antidepressants according to the DRUID classification, category I predominated over categories II and III. Our findings should serve as a starting point for health and traffic authorities to raise awareness of the risk for traffic accidents, especially involving SSRIs.

scholarly journals Childhood cancer incidence and survival in Thailand: A comprehensive population-based registry analysis, 1990-2011

2018 ◽  
Vol 66 (1) ◽  
pp. e27428 ◽  
Author(s):  
Serena S. Bidwell ◽  
Catherine C. Peterson ◽  
Kathryn Demanelis ◽  
Katie R. Zarins ◽  
Rafael Meza ◽  
...  
Keyword(s):  
Childhood Cancer ◽  
Cancer Incidence ◽  
Population Based ◽  
Population Based Registry ◽  
Registry Analysis

scholarly journals Clinical Profile, Treatment and Predictors during the First COVID-19 Wave: A Population-Based Registry Analysis from Castile and Leon Hospitals

2020 ◽  
Vol 17 (24) ◽  
pp. 9360
Author(s):  
Eduardo Gutiérrez-Abejón ◽  
Eduardo Tamayo ◽  
Débora Martín-García ◽  
F. Javier Álvarez ◽  
Francisco Herrera-Gómez
Keyword(s):  
Kidney Injury ◽  
Population Based ◽  
Ventilation Mode ◽  
Multiple Factors ◽  
High Incidence ◽  
Probability Of Death ◽  
Population Based Registry ◽  
Drug Use Pattern ◽  
Study Hospital ◽  
Registry Analysis

The first wave of the COVID-19 pandemic collapsed the hospitals in Castile and Leon (Spain). An analysis of the clinical characteristics, drug therapies and principal outcome predictors in the COVID-19 hospitalized patients from 1 March to 31 May 2020 is presented through a population-based registry study. Hospital stay variables, ventilation mode data and clinical outcomes were observed. In Castile and Leon hospitals, 7307 COVID-19 patients were admitted, with 57.05% being male and a median of 76 years. The mortality rate was 24.43%, with a high incidence of severe acute respiratory syndrome (SARS) (14.03%) and acute kidney injury (AKI) (10.87%). The most used medicines were antibiotics (90.83%), antimalarials (42.63%), steroids (44.37%) and antivirals, such as lopinavir/ritonavir (42.63%). The use of tocilizumab (9.37%) and anti-SIRS (systemic inflammatory response syndrome) medicines (7.34%) were remarkable. Fundamentally, death occurred more likely over 65 years of age (OR: 9.05). In addition, the need for ventilation was associated with a higher probability of death (OR: 3.59), SARS (OR: 5.14) and AKI (OR: 2.31). The drug-use pattern had been modified throughout the COVID-19 first wave. Multiple factors, such as age, gender and the need for mechanical ventilation, were related to the worst evolution prognosis of the disease.

scholarly journals Use of driving-impairing medicines by a Spanish population: a population-based registry study

BMJ Open ◽  
2017 ◽  
Vol 7 (11) ◽  
pp. e017618 ◽  
Author(s):  
Eduardo Gutierrez-Abejón ◽  
Francisco Herrera-Gómez ◽  
Paloma Criado-Espegel ◽  
F Javier Alvarez
Keyword(s):  
General Population ◽  
Census Data ◽  
Population Based ◽  
Spanish Population ◽  
Registry Study ◽  
Age And Gender ◽  
Patterns Of Use ◽  
And Gender ◽  
Population Based Registry ◽  
Chronic Use

ObjectiveTo assess the use of driving-impairing medicines (DIM) in the general population with special reference to length of use and concomitant use.DesignPopulation-based registry study.SettingThe year 2015 granted medicines consumption data recorded in the Castile and León (Spain) medicine dispensation registry was consulted.ParticipantsMedicines and DIM consumers from a Spanish population (Castile and León: 2.4 million inhabitants).ExposureMedicines and DIM consumption. Patterns of use by age and gender based on the length of use (acute: 1–7 days, subacute: 8–29 days and chronic use: ≥30 days) were of interest. Estimations regarding the distribution of licensed drivers by age and gender were employed to determine the patterns of use of DIM.ResultsDIM were consumed by 34.4% (95% CI 34.3% to 34.5%) of the general population in 2015, more commonly with regularity (chronic use: 22.5% vs acute use: 5.3%) and more frequently by the elderly. On average, 2.3 DIM per person were dispensed, particularly to chronic users (2.8 DIM per person). Age and gender distribution differences were observed between the Castile and León medicine dispensation registry data and the drivers’ license census data. Of all DIM dispensed, 83.8% were in the Anatomical Therapeutic Chemical code group nervous system medicines (N), which were prescribed to 29.2% of the population.ConclusionsThe use of DIM was frequent in the general population. Chronic use was common, but acute and subacute use should also be considered. This finding highlights the need to make patients, health professionals, health providers, medicine regulatory agencies and policy-makers at large aware of the role DIM play in traffic safety.

scholarly journals Clinical Profile, Pharmacological Treatment, and Predictors of Death Among Hospitalized COVID-19 Patients With Acute Kidney Injury: A Population-Based Registry Analysis

2021 ◽  
Vol 8 ◽  
Author(s):  
Eduardo Gutiérrez-Abejón ◽  
Débora Martín-García ◽  
Eduardo Tamayo ◽  
F. Javier Álvarez ◽  
Francisco Herrera-Gómez
Keyword(s):  
Acute Kidney Injury ◽  
Clinical Outcomes ◽  
Kidney Injury ◽  
Population Based ◽  
Hospital Death ◽  
Registry Study ◽  
Acute Dialysis ◽  
Population Based Registry ◽  
Very High ◽  
Registry Analysis

Introduction: One of the worst clinical outcomes of the coronavirus disease 2019 (COVID-19) pandemic was acute kidney injury (AKI).Methods: This manuscript presents results from a population-based registry study assessing treatment, comorbidities, and predictors of hospital death among COVID-19 patients with AKI from March 1st to May 31th, 2020. Death, oxygen delivery and ventilation, acute dialysis need, use of medications, and various clinical outcomes, in addition to the length of stay in the hospital and intensive care unit (ICU), were evaluated.Results: In Castile and Leon, the largest region of Spain, 10.87% of the patients admitted for COVID-19 (n = 7,307) developed AKI. These patients were known by having hypertension (57.93%), cardiovascular disease (48.99%), diabetes (26.7%) and chronic kidney disease (14.36%), and they used antibiotics (90.43%), antimalarials (60.45%), steroids (48.61%), antivirals (33.38%), anti-systemic inflammatory response syndrome (SIRS) drugs (9.45%), and tocilizumab (8.31%). Mortality among patients with AKI doubled that observed in patients without AKI (46.1 vs. 21.79%). Predictors of hospital death in COVID-19 patients with AKI were ventilation needs (OR = 5.9), treatment with steroids (OR = 1.7) or anti-SIRS (OR = 2.4), severe acute respiratory syndrome (SARS) occurrence (OR = 2.8), and SIRS occurrence (OR = 2.5).Conclusions: Acute kidney injury is a frequent and serious complication among COVID-19 patients, with a very high mortality, that requires more attention by treating physicians, when prescribing medications, by looking for manifestations particular to the disease, such as SARS or SIRS.

scholarly journals Incidence of Type 1 Diabetes May Be Underestimated in the Chinese Population: Evidence From 21.7 Million People Between 2007 and 2017

2021 ◽  
Author(s):  
Chang Liu ◽  
Ying-Chao Yuan ◽  
Mo-Ning Guo ◽  
Zhong Xin ◽  
Guan-Jie Chen ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Chinese Population ◽  
Age Groups ◽  
Population Based ◽  
Annual Incidence ◽  
Age Group ◽  
And Gender ◽  
Population Based Registry ◽  
Design And Methods

OBJECTIVE─ Previous reports of the annual incidence of type 1 diabetes (T1D) in China were conducted using retrospective hospital cases, which may not reflect the reality. This longitudinal study estimated T1D incidence in a 21.7-million Chinese population during 2007-2017. <p>RESEARCH DESIGN AND METHODS─ A population-based registry of T1D was performed by the Beijing Municipal Health Commission Information Center. Annual incidence and 95% confidence intervals (CI) were calculated by age group and gender. The association of gender with T1D incidence and predicted new T1D cases were assessed using Poisson regression models. Annual percentage change and average annual percentage of change were assessed using Joinpoint regression. </p> <p>RESULTS─ Overall, there were 6,875 individuals who developed T1D from 2007 to 2017 in this population. T1D incidence [95% CI] (/100,000 persons) significantly increased from 2.72 [2.51, 2.93] in 2007 to 3.60 [3.38, 3.78] in 2017 (p<0.001). The T1D onset peak was in the 10-14 age group. While no significant trend was found in the 0-14 and 15-29 age groups, T1D incidence markedly increased from 1.87 to 3.52 in ≥30 age group (p<0.05). The prevalence of diabetic ketoacidosis at diagnosis was highest in 0-4 age group. We predicted T1D new cases will increase to 1.57-fold over the next decade. </p> CONCLUSIONS─ T1D incidence in this large Chinese population is higher than has been reported previously. During 2007-2017, although the incidence peak was in the 10-14 age group, the T1D incidence increased sharply in adults but not in youth.

An analysis of the temporal, age, and gender trends in human papillomavirus virus (HPV)-related versus non-HPV-related head and neck cancers (HNC) in Alberta, Canada.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e12505-e12505
Author(s):  
Desiree Hao ◽  
Harold Y. Lau ◽  
Longlong Huang ◽  
Corinne M. Doll ◽  
Joseph C. Dort ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Head And Neck ◽  
Population Based ◽  
Epidemiologic Studies ◽  
Incidence Rates ◽  
Gender And Age ◽  
Younger Men ◽  
And Gender ◽  
Population Based Registry ◽  
Over Time

e12505 Background: Recent epidemiologic studies have suggested that the incidence of HPV-associated HNC is increasing. This study assessed temporal, age-specific and gender specific changes in cancer incidence for HPV- versus non-HPV associated HNC compared with other HPV versus non-HPV associated malignancies in a population-based setting. Methods: We used the Alberta Cancer Registry, a population-based registry of all cancers diagnosed in the province of Alberta, Canada (population est. 3.6 million), to identify patients diagnosed with cancers of the oropharynx, cervix, vulva, vagina, anus, and penis (HPV-associated group) and compared this with non-oropharyngeal cancers of the head and neck and lung cancer (non-HPV associated, modifiable risk group) between January 1, 1975 and December 31, 2009. The age-standardized incidence rates (ASIR) for each cancer by gender and age-specific incidence was estimated with the annual percentage change (APC) assessed using Joinpoint regression. Results: The ASIR for oropharyngeal cancers (OPC) increased over time for both men (APC 3.5) and women (APC 1.5) with rapid increases seen in men under 35 (APC 27.3). Non-oropharyngeal squamous cell carcinomas of the head and neck had a higher ASIR overall with moderate temporal increases (APC 2.5) and age-specific increases highest in those aged 55 to 74. ASIR for anal canal cancers also increased over time, with greater increases amongst younger females, in contrast to OPC. By comparison, the ASIR of cervix cancer declined with more significant decreases in younger females; while the rates of other HPV-associated cancers (vulva, vagina, penile) showed little change. The ASIR for lung cancer decreased after 1987 (APC -1.5) for men and continued to moderately increase for women. Conclusions: Our findings suggest the greatest increases in OPC are occurring in younger men. Programs of HPV prevention such as vaccination should be explored to reduce the incidence of OPC in males.

scholarly journals The Trends in Opioid Use in Castile and Leon, Spain: A Population-Based Registry Analysis of Dispensations in 2015 to 2018

2019 ◽  
Vol 8 (12) ◽  
pp. 2148 ◽  
Author(s):  
Francisco Herrera-Gómez ◽  
Eduardo Gutierrez-Abejón ◽  
Ignacio Ayestarán ◽  
Paloma Criado-Espegel ◽  
F. Javier Álvarez
Keyword(s):  
Opioid Analgesics ◽  
The Elderly ◽  
Population Based ◽  
Common Finding ◽  
Opioid Use ◽  
Safe Driving ◽  
Frequent Use ◽  
And Gender ◽  
Multiple Drugs ◽  
Population Based Registry

Opioids are driving-impairing medicines (DIM). To assess the evolution and trends of opioid analgesics use between 2015 and 2018 in Castile and Leon (Spain), a population-based registry study was conceived. The length of opioid use and its concomitant use with other DIMs were studied. Analyses were done considering age and gender distributions. Adjusted consumption for licensed drivers is also presented. Of the 5 million dispensations recorded between 2015 and 2018, opioid analgesics were dispensed to 11.44% of the general population and 8.72% of vehicle drivers. Increases among daily users (2.6 times higher) and chronic users (1.5% higher) were noted, supporting the overall increase in opioid use (1.5%). The use of multiple drugs including other DIMs was a common finding (mean ± SD, 2.54 ± 0.01). Acute use (5.26%) and chronic use (3.20%) were also frequent. Formulations combining opioid analgesics with nonopioid analgesics were preferred. The use of opioids increased in Spain between 2015 and 2018. Concomitant use with other DIMS especially affects women and the elderly. Frequent use of opioid analgesics with other DIMs is a serious problem for drivers and increases the risk of accidents. Promoting safe driving should be a main objective of health authorities, to be achieved by developing and implementing educational activities for healthcare professionals and patients.

Sign in / Sign up

Export Citation Format

Share Document